Treatment of exacerbations of multiple sclerosis without the use of corticosteroids: The role of metabolic and antioxidant therapy

Neuroscience and Behavioral Physiology

Volumn 42, Issue 2, 2012, Pages 123-127

  Bisaga, G N ^a   Odinak, M M ^a   Boiko, A N ^b   Melnik, Yu B ^a   Popova, N F ^b  

^a S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

^b Moscow City Multiple Sclerosis Center   (Russian Federation)

Author keywords

antioxidant treatment; Cytoflavin; exacerbation; metabolic treatment; multiple sclerosis

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; CYTOFLAVIN; MYELIN BASIC PROTEIN ANTIBODY; PENTOXIFYLLINE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VITAMIN B GROUP;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BODY RASH; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FACE RASH; HOT FLUSH; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NECK RASH; OLIGOPHRENIA; RANDOMIZED CONTROLLED TRIAL; THROAT DISEASE; THROAT TICKLE; VERTIGO;

EID: 84857636290     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-011-9544-0     Document Type: Article

References (14)

1. V. V. Afanasiev and I. Yu. Lukyanova, Features of the Use of Cytoflavin in Current Clinical Practice [in Russian], St. Petersburg (2010).
2. VB Gavrilov AR Gavrilova LM Mazhul 1987 Analysis of methods for estimating serum lipid peroxidation products with thiobarbituric acid Vopr. Med. Khim. 33 1 118 122 2437702 1:CAS:528:DyaL2sXhtFGqtbY%3D (Pubitemid 17233337)
3. EE Dubinina SO Burmistrov DA Khodov IS Porotov 1995 Oxidative modification of human serum proteins Assay methods Vopr. Med. 41 1 24 26 1:CAS:528:DyaK2MXovVSlur8%3D
4. AL Kovalenko MN Bizenkova VV Bulon, et al. 2006 Pathogenetic basis and pharmacotherapeutic efficacy of the use of Cytoflavin in acute cerebral ischemia SPbMGA 3 79 83
5. M. M. Odinak, G. N. Gisaga, and I. V. Zarubina, "New approaches to antioxidant therapy in multiple sclerosis," Zh. Nevrol. Psikhiat., Special issue on Multiple Sclerosis, 72-75 (2002).
6. I. D. Stalnaya and T. G. Gorishvili, "A method for estimating malondialdehye with thiobarbituric acid," in: Current Methods in Biochemistry [in Russian], V. N. Orekhovich (ed.), Meditsina, Moscow (1977), pp. 66-68.
7. JF Kurtzke 1983 Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1444 1452 6685237 1:STN:280:DyaL2c%2FktValsQ%3D%3D (Pubitemid 14237132)
8. PR Lyons PK Newman M Saunders 1988 Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects J. Neurol. Neurosurg. Psychiat. 51 2 285 287 3346696 10.1136/jnnp.51.2.285 1:STN:280:DyaL1c7lsV2htw%3D%3D (Pubitemid 18055141)
9. K. M. Myhr and S. I. Mellgren, "Corticosteroids in the treatment of multiple sclerosis," Acta Neurol. Scand., Suppl., 73-80 (2009).
10. M Namaka R Vandenbosch R Gill, et al. 2005 Corticosteroids and multiple sclerosis: to treat or not to treat Can. Pharm. J. 138 6 1 13
11. CH Polman SC Reingold G Edan, et al. 2005 Diagnostic criteria for multiple sclerosis: 2005 revision to the McDonald Criteria Ann. Neurol. 58 840 846 16283615 10.1002/ana.20703 (Pubitemid 41746873)
12. CM Poser DW Paty L Scheinberg, et al. 1983 New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann. Neurol. 13 227 231 6847134 10.1002/ana.410130302 1:STN:280:DyaL3s3gt1OgtQ%3D%3D (Pubitemid 13158528)
13. A. Scalfari, A. Neuhaus, A. Degenhardt, et al., "The natural history of multiple sclerosis: a geographically based study. 10: relapses and long-term disability," Brain, 133, No. 7, 1914-1929 (2010).
14. 3 exposed rat lungs Arch. Env. Health 37 3 167 176 1:CAS:528:DyaL38XmtV2rtb8%3D (Pubitemid 12044319)